AI-Designed Candidate for Idiopathic Pulmonary Fibrosis Enters Phase 2 Trials
A major milestone for computational drug discovery as the first fully AI-generated drug candidate enters Phase 2 clinical trials, testing efficacy in human patients.
Insilico Medicine
Private
Insilico Medicine is an end-to-end generative artificial intelligence-driven drug discovery company connecting biology, chemistry, and clinical trials analysis.
Company Info
Sector: AI Drug Discovery / TechBio
Headquarters: New York, New York, USA
Founded: 2014
Website: insilico.com
Funding Round: Series D-2
Total Funding: $415M
Funding & Investor Relations
Notable Investors
- Warburg Pincus
- Qiming Venture Partners
- Deerfield Management
- B Capital Group
- Maison Capital
- OrbiMed
IPO Outlook / Plans
Reportedly planning to file for a Hong Kong Stock Exchange (HKEX) listing in late 2026 / early 2027, depending on market conditions.
Upcoming Milestones & Key Dates
August 15, 2026
Clinical Trial
Interim Phase 2 Safety & Tolerability Data Release for ISM001-055
October 22, 2026
Conference
Keynote Lecture at Global AI in Drug Discovery Summit
Clinical Development Pipeline
ISM001-055
Target: TRAF2 & NCK-interacting kinase (TNIK)ISM3091
Target: USP1 InhibitorISM8207
Target: QPCTL InhibitorRecent News
Leadership Team
Careers & Job Openings